A Step Ahead in Secondary Prevention of Cardiovascular Risk. Consensus Document on Clinical Use of the Polypill

Rev Esp Cardiol (Engl Ed). 2016 Jun;69(6):547-50. doi: 10.1016/j.rec.2016.02.008. Epub 2016 Apr 6.
[Article in English, Spanish]
No abstract available

Publication types

  • Consensus Development Conference
  • Editorial

MeSH terms

  • Angiotensin-Converting Enzyme Inhibitors / therapeutic use*
  • Aspirin / therapeutic use*
  • Atorvastatin / therapeutic use*
  • Cardiovascular Diseases / drug therapy*
  • Drug Combinations
  • Europe
  • Humans
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use*
  • Medication Adherence
  • Patient Selection
  • Platelet Aggregation Inhibitors / therapeutic use*
  • Practice Guidelines as Topic
  • Ramipril / therapeutic use*
  • Secondary Prevention*
  • Spain

Substances

  • Angiotensin-Converting Enzyme Inhibitors
  • Drug Combinations
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors
  • Platelet Aggregation Inhibitors
  • Atorvastatin
  • Ramipril
  • Aspirin